Pierre‐Régis Burgel

Délégation Paris 5 — France

Medicine · Health Sciences

63h-index13.7kcitations636works6.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cystic Fibrosis Research Advances(282), Chronic Obstructive Pulmonary Disease (COPD) Research(172), Neonatal Respiratory Health Research(109), Tracheal and airway disorders(105), Asthma and respiratory diseases(84)

Publications628 total

EE594 NCFBE Hospitalizations Costs Across Different Healthcare Systems: Insights From England and France in 2022 Using PMSI and HES Databases
Value in Health·2025
Advances in cystic fibrosis: CFTR modulator triple combinations
European Respiratory Journal·2025· 2 citedOpen Access
Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model
The Lancet Respiratory Medicine·2025· 1 cited
P4 Multidimensional classification for severity of exacerbations of COPD: the COPD exacerbation BAT (baseline, acuity, and trigger) conceptual model
2025· 1 cited
S38 Effects of brensocatib on neutrophil serine protease levels in patients with non-cystic fibrosis bronchiectasis: a pharmacodynamic analysis of the ASPEN trial
2025
Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France
International Journal of COPD·2025Open Access
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR
Frontiers in Pharmacology·2025Open Access
Cytosolic proliferating cell nuclear antigen (PCNA) orchestrates neutrophil hyperactivation in COVID-19
Proceedings of the National Academy of Sciences·2025Open Access
Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor
Journal of Cystic Fibrosis·2025· 4 citedOpen Access
Pregnancy after lung transplantation: TRIGGER study on antihuman leukocyte antigen alloimmunization and antibody-mediated rejection risk
The Journal of Heart and Lung Transplantation·2025· 1 cited
Identification of structural predictors of lung function improvement in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor using deep-learning
Diagnostic and Interventional Imaging·2025· 2 citedOpen Access
EFFICACY AND SAFETY OF BRENSOCATIB IN PATIENTS OF ASIAN RACE WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS: A SUBGROUP ANALYSIS OF THE ASPEN TRIAL
CHEST Journal·2025· 1 citedOpen Access
THE EFFECT OF BRENSOCATIB VS PLACEBO ON SYMPTOM BURDEN IN PATIENTS WITH OR WITHOUT ON-STUDY PULMONARY EXACERBATIONS: A POSTHOC ANALYSIS FROM THE ASPEN TRIAL
CHEST Journal·2025
475 Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ ivacaftor in children with cystic fibrosis: extrapolation of the dosing regimen in children under 2 years of age
Journal of Cystic Fibrosis·2025
EFFECTS OF BRENSOCATIB ON NEUTROPHIL SERINE PROTEASE LEVELS IN PATIENTS WITH NONCYSTIC FIBROSIS BRONCHIECTASIS: AN ANALYSIS OF THE ASPEN TRIAL
CHEST Journal·2025
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis
European Respiratory Journal·2025· 30 cited
Multidimensional classification for severity of exacerbations of COPD: The COPD Exacerbation BAT (Baseline, Acuity, and Trigger) conceptual model
2025
Respiratory pathogen clusters in patients with bronchiectasis: Data from the EMBARC registry.
2025
Trajectory of lower airway bacterial colonization in patients with primary ciliary dyskinesia
2025
Lobar differences on chest CTs of bronchiectasis patients from the EMBARC registry
2025
page 1 of 32Next →

Frequent Co-authors

Nicolás Roche(14), Daniel Dusser(12), T. Pérez(9), Isabelle Sermet‐Gaudelus(9), Pascal Chanez(8), D. Hubert(8), Dominique Grenet(7), Clémence Martin(7), Reem Kanaan(7), I. Durieu(6), R. Chiron(6), Anne Prévötat(6), Julie Macey(6), Jean-Louis Paillasseur(6), D. Caillaud(5), Laurent Mély(5), Lydie Lemonnier(5), Harriet Corvol(5), Scott C. Bell(4), Francesco Blasi(4)